Evidence map›Paper›PMID 42746216›Full record

ArticleOpen medicine (Warsaw, Poland)2026

Follow-up-dependent calendar-period associations with cardiac mortality after lung cancer radiotherapy: a competing-risks SEER analysis.

Na Zhang, Siyu Chen, Jingyi Ai, Chaoxing Liu, Ye Zhou, Yajing Wu, Jun Wang

Abstract read
In one paragraph

Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Na ZhangDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, China.ORCID https://orcid.org/0009-0009-2344-8442
Siyu ChenDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, China.ORCID https://orcid.org/0009-0001-0170-7820
Jingyi AiDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, China.ORCID https://orcid.org/0009-0002-4190-157X
Chaoxing LiuDepartment of Radiation Oncology, Shijiazhuang People's Hospital, Shijiazhuang, China.ORCID https://orcid.org/0000-0002-0299-3312
Ye ZhouDepartment of Oncology, Hebei General Hospital, Shijiazhuang, China.
Yajing WuDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, China.ORCID https://orcid.org/0000-0003-2079-0348
Jun WangDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, China.ORCID https://orcid.org/0000-0002-9733-1433

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Calendar-period comparisons of cardiac mortality after thoracic radiotherapy can be distorted by competing cancer death and by unequal follow-up, because more recently diagnosed patients are observed for less time. We aimed to determine whether a reported recent-era decline in cardiac mortality after lung radiotherapy reflects changing practice or analytic artifact. Methods: We identified 56,241 patients with lung and bronchus cancer diagnosed in 2009-2021 in the SEER database (28,246 beam radiotherapy without surgery; 27,995 surgery without radiotherapy; chemotherapy-recorded patients excluded). Cardiac death was the event of interest and lung cancer death the competing event. In each cohort we estimated Fine-Gray subdistribution hazard ratios (sHRs) for diagnosis period under (i) full follow-up, (ii) full follow-up restricted to diagnoses through 2018, and (iii) a fixed 36-month window for that same 2009-2018 cohort. We additionally estimated period sHRs across fixed windows of 12-60 months, repeated all models treating other-cause deaths as competing events and using cause-specific Cox regression, and tested the proportional-subdistribution-hazards assumption. Results: In the radiotherapy cohort, more recent diagnosis was associated with a lower subdistribution hazard of cardiac death under full follow-up (sHR 0.761; 95 % CI 0.678-0.854; p<0.001), but the association was not significant at any equalized follow-up window (12-month sHR 0.864; 24-month 0.918; 36-month 0.994 [0.853-1.157]; 48-month 0.944; 60-month 1.026; all p≥0.14), and the period effect was non-proportional over follow-up time (p=0.003). The attenuation persisted when other-cause deaths were treated as competing events (36-month sHR 1.000) and under cause-specific regression (36-month HR 0.898; p=0.167), and median follow-up differed markedly by period (108 vs. 38 months). By contrast, the surgery cohort retained a significantly lower recent-period estimate through 36 months under the same matched-window analysis (restricted-full sHR 0.734; 36-month sHR 0.770; p=0.017), attenuating only at 48-60 months. Conclusions: A recent-period reduction in the surgery cohort persisted through a 36-month matched window, showing that matched-window analysis does not mechanically null a calendar-period signal; by contrast, the radiotherapy cohort showed no such association at any comparable follow-up. Registry data therefore do not support attributing a cardiac-mortality decline to changes in radiotherapy practice, and temporal registry comparisons must use comparable follow-up windows, account for competing death, and verify proportionality before such attribution.

Indexed as

cardio-oncologycompeting risksFine–Gray modelfollow-up durationregistry studysubdistribution hazard

Identifiers

PMID42746216
PMCPMC13576467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.